Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on developing precision genetic medicines, has granted 55,450 restricted stock units (RSUs) to four new employees. The RSUs will vest over a four-year period, with 25% vesting annually on each grant date anniversary. The equity awards were issued under the company's 2024 Inducement Stock Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB), un'azienda nel settore delle scienze della vita specializzata nello sviluppo di terapie genetiche di precisione, ha assegnato 55.450 unità di azioni vincolate (RSU) a quattro nuovi dipendenti. Le RSU matureranno nell'arco di quattro anni, con il 25% che matura ogni anno nell'anniversario della data di assegnazione. Le azioni sono state emesse nell'ambito del Piano di Incentivi Azionari 2024 dell'azienda, in conformità con la Regola Nasdaq 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB), una empresa de ciencias de la vida enfocada en el desarrollo de medicamentos genéticos de precisión, ha otorgado 55,450 unidades restringidas de acciones (RSUs) a cuatro nuevos empleados. Las RSUs se consolidarán en un período de cuatro años, con un 25% consolidándose anualmente en cada aniversario de la fecha de concesión. Las acciones se emitieron bajo el Plan de Incentivos de Acciones por Inducción 2024 de la compañía, en cumplimiento con la Regla 5635(c)(4) de Nasdaq.
Solid Biosciences (Nasdaq: SLDB)는 정밀 유전 의약품 개발에 주력하는 생명과학 회사로, 네 명의 신입 직원에게 55,450개의 제한 주식 단위(RSU)를 부여했습니다. RSU는 4년 동안 매년 부여일 기념일에 25%씩 점진적으로 취득됩니다. 이 주식 보상은 2024년 유인 주식 인센티브 계획에 따라 발행되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Solid Biosciences (Nasdaq : SLDB), une entreprise des sciences de la vie spécialisée dans le développement de médicaments génétiques de précision, a accordé 55 450 unités d’actions restreintes (RSU) à quatre nouveaux employés. Les RSU seront acquises sur une période de quatre ans, avec 25 % qui seront acquis chaque année à l’anniversaire de la date d’attribution. Les attributions d’actions ont été émises dans le cadre du Plan d’Incitation à l’Attribution d’Actions 2024 de la société, conformément à la règle 5635(c)(4) du Nasdaq.
Solid Biosciences (Nasdaq: SLDB), ein Life-Sciences-Unternehmen, das sich auf die Entwicklung präziser genetischer Medikamente spezialisiert hat, hat vier neuen Mitarbeitern 55.450 Restricted Stock Units (RSUs) gewährt. Die RSUs werden über einen Zeitraum von vier Jahren ausgegeben, wobei jährlich 25 % am Jahrestag des jeweiligen Zuteilungsdatums freigegeben werden. Die Aktien wurden im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens ausgegeben und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted stock units (“RSUs”) to four newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
How many RSUs did Solid Biosciences (SLDB) grant to new employees in August 2025?
What is the vesting schedule for Solid Biosciences' (SLDB) August 2025 RSU grants?
Under which plan were Solid Biosciences' (SLDB) August 2025 RSU grants issued?
What happens to the RSUs if an employee leaves Solid Biosciences (SLDB)?
